Sulfonylureas and Cardiovascular Safety
Open Access
- 24 September 2019
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 322 (12), 1147-1149
- https://doi.org/10.1001/jama.2019.14533
Abstract
As the options for glucose-lowering medications for patients with type 2 diabetes have expanded, the choices for physicians and patients have become more difficKeywords
This publication has 14 references indexed in Scilit:
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert ForumDiabetes Care, 2017
- Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic EventsDiabetes Care, 2017
- Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical EvidenceTrends in Endocrinology & Metabolism, 2017
- Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational StudiesDiabetes Care, 2017
- Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival dataDiabetes, Obesity and Metabolism, 2016
- Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 DiabetesJAMA, 2016
- Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes MellitusAnnals of Internal Medicine, 2012
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular EventsDiabetes Care, 2007
- "Settling the UGDP Controversy"?JAMA, 1975